An investigational stem cell therapy derived from patients' own blood marrow significantly improved outcomes in patients with severe heart failure, according to a study from the Cedars-Sinai Heart ...
TO THE STUDY’S FIRST PATIENT. 82 YEAR OLD LOUIS MEYER HAD A HEART ATTACK OVER 25 YEARS AGO, AND EVER SINCE HE’S DONE EVERYTHING HE CAN TO MANAGE IT, THE DAMAGED PART STARTS TAKING OVER. THAT’S THE ...
Patients with weak heart function who receive stem cell therapy shortly after a heart attack are at lower risk of developing heart failure and related hospital stays compared with standard care, finds ...
Millions of people around the world die from heart failure every year. In future, a laboratory-grown heart patch could help with severe cases of cardiovascular disease, say scientists behind a ...
Patients with weak heart function who receive stem cell therapy shortly after a heart attack are at lower risk of developing heart failure and related hospital stays compared with standard care, finds ...
The existing clinical data supporting safety and efficacy of CardiAMP Cell Therapy for HFrEF is subject to ongoing regulatory discussions in Japan and the United States. The compilation includes data ...
CardiAMP cell therapy-treated patients had 37% relative risk reduction in heart death equivalent (death, heart transplant, left ventricular assist device implantation) and 9% relative risk reduction ...
CHICAGO — For patients with advanced heart failure, an injection of autologous mononuclear cells into damaged myocardia missed the primary endpoint in the sham-controlled, randomized, blinded CardiAMP ...
A critical review of cell-based and cell product-based therapies for the treatment of heart failure details 20 years of completed and ongoing clinical trials. While none has yet gained medical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback